Review and management of drug interactions with boceprevir and telaprevir

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Hepatology

• Publication date

  2012-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/hep.25653PMID 22331658PMCID PMC3345276
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3.

  2013cited by this paper
• Pharmacokinetic Evaluation of the Interaction between Hepatitis C Virus Protease Inhibitor Boceprevir and 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Atorvastatin and Pravastatin

  2013cited by this paper
• The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers

  2013cited by this paper
• Important Drug-Drug Interactions in HIV-Infected Persons on Antiretroviral Therapy: An Update on New Interactions Between HIV and Non-HIV Drugs

  2012cited by this paper
• Steady‐State Pharmacokinetic Interactions of Darunavir/Ritonavir With Lipid‐Lowering Agent Rosuvastatin

  2012cited by this paper
• Bioavailability of the HCV NS3/4A Protease Inhibitor Telaprevir – Effect of Different Types of Food

  2012cited by this paper
• The Pharmacokinetic Interaction Between an Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone and the HCV Protease Inhibitor Telaprevir

  2012cited by this paper
• Boceprevir plus peginterferon/ribavirin for the treatment of HCV/HIV co-infected patients

  2012influential reference
• Effect of Telaprevir on the Pharmacokinetics of Midazolam and Digoxin

  2012cited by this paper
• Effect of the Hepatitis C Virus Protease Inhibitor Telaprevir on the Pharmacokinetics of Amlodipine and Atorvastatin

  2011cited by this paper
• Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C.

  2011cited by this paper
• Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus

  2011cited by this paper
• 1244 THE PHARMACOKINETIC INTERACTION BETWEEN METHADONE AND THE INVESTIGATIONAL HCV PROTEASE INHIBITOR TELAPREVIR

  2011cited by this paper
• Boceprevir for previously treated chronic HCV genotype 1 infection.

  2011cited by this paper
• Telaprevir for previously untreated chronic hepatitis C virus infection.

  2011cited by this paper
• Response-guided telaprevir combination treatment for hepatitis C virus infection.

  2011cited by this paper
• Boceprevir for Untreated Chronic HCV Genotype 1 Infection

  2011cited by this paper
• Boceprevir for untreated chronic HCV genotype 1 infection.

  2011cited by this paper
• Telaprevir for retreatment of HCV infection.

  2011cited by this paper
• 1245 THE EFFECT OF SEVERE RENAL IMPAIRMENT ON THE PHARMACOKINETICS OF THE INVESTIGATIONAL HCV PROTEASE INHIBITOR TELAPREVIR

  2011cited by this paper
• HIV/HCV Co-infection: Pathogenesis, Clinical Complications, Treatment, and New Therapeutic Technologies

  2011cited by this paper
• Progestin-only pills for contraception.

  2010cited by this paper
• Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients.

  2010cited by this paper
• Issues in drug metabolism of major antihypertensive drugs: β-blockers, calcium channel antagonists and angiotensin receptor blockers

  2010influential reference
• Increased Aripiprazole Concentrations in an HIV-Positive Male Concurrently Taking Duloxetine, Darunavir, and Ritonavir

  2010cited by this paper
• Effects of Atazanavir/Ritonavir or Fosamprenavir/Ritonavir on the Pharmacokinetics of Rosuvastatin

  2008cited by this paper
• Major depressive disorder.

  2008cited by this paper
• Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy.

  2008cited by this paper
• Drug/Drug Interaction Between Lopinavir/Ritonavir and Rosuvastatin in Healthy Volunteers

  2008cited by this paper
• Viral hepatitis and HIV coinfection.

  2008influential reference
• Immunosuppressant Pharmacokinetics and Dosing Modifications in HIV‐1 Infected Liver and Kidney Transplant Recipients

  2007cited by this paper
• Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir.

  2007cited by this paper
• Pharmacokinetic interaction between TMC114/ritonavir and tenofovir disoproxil fumarate in healthy volunteers.

  2007cited by this paper
• Effect of Highly Active Antiretroviral Therapy on Tacrolimus Pharmacokinetics in Hepatitis C Virus and HIV Co-Infected Liver Transplant Recipients in the ANRS HC-08 Study

  2007cited by this paper
• Pharmacokinetics and Safety of Tenofovir Disoproxil Fumarate on Coadministration With Lopinavir/Ritonavir

  2006cited by this paper
• Pharmacokinetic interaction between Amprenavir/Ritonavir and FosAmprenavir on cyclosporine in two patients with human immunodeficiency virus infection undergoing orthotopic liver transplantation.

  2006cited by this paper
• Management of drug‐to‐drug interactions between cyclosporine A and the protease‐inhibitor lopinavir/ritonavir in liver‐transplanted HIV‐infected patients

  2004cited by this paper
• Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19.

  2004cited by this paper
• Evaluation of Single and Multiple Dose Pharmacokinetics of Ritonavir in Subjects with Mild or Moderate Hepatic Insufficiency

  2003cited by this paper
• Short‐Term Exposure to Low‐Dose Ritonavir Impairs Clearance and Enhances Adverse Effects of Trazodone

  2003cited by this paper
• Implications of cytochrome P450 interactions when prescribing medication for hypertension.

  2002cited by this paper
• CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW

  2002influential reference
• Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase Inhibitors

  2002cited by this paper
• Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000

  1998cited by this paper
• The metabolism and excretion of buprenorphine in humans.

  1984cited by this paper

• Multigram Synthesis of Bicyclic α- and β-Prolines via Intramolecular C(sp3)-H γ-Lactamization as a Key Step.

  2025cites this paper
• New Saturated Bicyclic Pyrrolidines: The Multigram Synthesis and Orthogonal Functionalization

  2025cites this paper
• Effect of Hepatitis C Virus Genotype, Cirrhosis, and Viral Cure on Serum Phosphatidylinositol Species Profiles

  2025cites this paper
• Rising Lysophosphatidylcholine Levels Post-Hepatitis C Clearance

  2024cites this paper
• Serum Phosphatidylcholine Species 32:0 as a Biomarker for Liver Cirrhosis Pre- and Post-Hepatitis C Virus Clearance

  2024cites this paper
• The Role of CYPs and Transporters in the Biotransformation and Transport of the Anti-hepatitis C Antiviral Agents Asunaprevir, Daclatasvir, and Beclabuvir: Impact of Liver Disease, Race and Drug-drug Interactions on Safety and Efficacy.

  2024cites this paper
• Mechanisms and Clinical Significance of Pharmacokinetic Drug Interactions Mediated by FDA and EMA-approved Hepatitis C Direct-Acting Antiviral Agents

  2023cites this paper
• Discovery of a fused bicyclic derivative of 4-hydroxypyrrolidine and imidazolidinone as a new anti-HCV agent.

  2023cites this paper
• Analysis of Patients’ Characteristics and Treatment Profile of People Who Use Drugs (PWUDs) with and without a Co-Diagnosis of Viral Hepatitis C: A Real-World Retrospective Italian Analysis

  2023cites this paper
• Effects of a ritonavir‐containing regimen on the pharmacokinetics of sirolimus or everolimus in healthy adult subjects

  2022cites this paper
• Discovery of Novel 1,2,3-triazole Derivatives as IDO1 Inhibitors

  2022cites this paper
• Breakthroughs in hepatitis C research: from discovery to cure

  2022cites this paper
• Synthesis and Anti-Tumor Effects of Novel Pomalidomide Derivatives Containing Urea Moieties

  2022cites this paper
• Daclatasvir as a hepatitis C infection treatment option: an up-to-date evaluation

  2022cites this paper
• Rapid Decline of Serum Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) in Non-Cirrhotic Patients with Chronic Hepatitis C Infection Receiving Direct-Acting Antiviral Therapy

  2021cites this paper
• Medicinal chemistry strategies for discovering antivirals effective against drug-resistant viruses.

  2021cites this paper
• Targeting SARS-CoV-2 M3CLpro by HCV NS3/4a Inhibitors: In Silico Modeling and In Vitro Screening

  2021cites this paper
• Drug‐Drug Interaction Studies With Oral Contraceptives: Pharmacokinetic/Pharmacodynamic and Study Design Considerations

  2020cites this paper
• Potential Inhibitors for Novel Coronavirus Protease Identified by Virtual Screening of 606 Million Compounds

  2020cites this paper
• Host-targeting therapies for hepatitis C virus infection: current developments and future applications

  2018cites this paper
• Treatment optimization for HIV/HCV co-infected patients

  2017cites this paper
• PIM-Check: development of an international prescription-screening checklist designed by a Delphi method for internal medicine patients

  2017cites this paper
• Intrahepatic Sampling for the Elucidation of Antiviral Clinical Pharmacology

  2017cites this paper
• Statin (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor)-based therapy for hepatitis C virus (HCV) infection-related diseases in the era of direct-acting antiviral agents

  2017cites this paper
• Celastrol inhibits hepatitis C virus replication by upregulating heme oxygenase-1 via the JNK MAPK/Nrf2 pathway in human hepatoma cells

  2017influential citation
• New directions for protease inhibitors directed drug discovery

  2016cites this paper
• Statin (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor)-based therapy for hepatitis C virus (HCV) infection-related diseases in the era of direct-acting antiviral agents.

  2016cites this paper
• Statin (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor)-based therapy for hepatitis C virus (HCV) infection-related diseases in the era of direct-acting antiviral agents.

  2016cites this paper
• Efficacy and Tolerability of Pegylated Interferon and Ribavirin in Combination with Simeprevir to Treat Hepatitis C Virus Infections After Living Donor Liver Transplantation

  2016cites this paper
• Enfermedades Infecciosas y Microbiología Clínica

  2016cites this paper
• New era in treatment options of chronic hepatitis C: focus on safety of new direct-acting antivirals (DAAs)

  2016cites this paper
• Early reduced liver graft survival in hepatitis C recipients identified by two combined genetic markers

  2016cites this paper
• Study designs and statistical methods for pharmacogenomics and drug interaction studies

  2016cites this paper
• The era of first direct‐acting antiviral agents: What did we learn?

  2016cites this paper
• CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment

  2016influential citation
• PEGYLATED INTERFERON AND RIBAVIRIN FOR TREATMENT OF RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION: a single-liver transplant center experience in Brazil.

  2015cites this paper
• 156 – Hepatitis C

  2015cites this paper
• Liver Transplantation Update: 2014

  2015cites this paper
• New Perspective in HCV Clinical and Economical Management of the Current and Future Therapies

  2015cites this paper
• Lipid dysregulation in hepatitis C virus, and impact of statin therapy upon clinical outcomes.

  2015cites this paper
• Safely treating hepatitis C in patients with HIV or hepatitis B virus coinfection

  2015cites this paper
• What psychiatric screening and monitoring might be needed with the new generation of hepatitis C treatments?

  2015cites this paper
• LC-ESI-MS/MS Analysis and Pharmacokinetics of GP205, an Innovative Potent Macrocyclic Inhibitor of Hepatitis C Virus NS3/4A Protease in Rats

  2015cites this paper
• Liver transplantation in the context of organ shortage: toward extension and restriction of indications considering recent clinical data and ethical framework

  2015cites this paper
• Evaluating Andrographolide as a Potent Inhibitor of NS3-4A Protease and Its Drug-Resistant Mutants Using In Silico Approaches

  2015cites this paper
• Drug–drug interactions of telaprevir and boceprevir in HCV‐monoinfected and HIV/HCV‐coinfected patients can modify the adherence

  2015influential citation
• New hepatitis C virus therapies: drug classes and metabolism, drug interactions relevant in the transplant settings, drug options in decompensated cirrhosis, and drug options in end-stage renal disease

  2015cites this paper
• Effects of Antiviral Drugs on Organic Anion Transport in Human Placental BeWo Cells

  2015cites this paper
• Considerations on the role of buprenorphine in recovery from heroin addiction from a UK perspective

  2015cites this paper
• Management of HCV in the liver transplant setting.

  2015cites this paper
• Education and training

  2015cites this paper
• Hepatitis C in children in times of change

  2015cites this paper
• KEY POINTS ACLF is a newly defined syndrome characterized by the presence of organ failures and high short-term mortality rate in patients with acute decompensation of cirrhosis that may benefit from liver transplantation

  2015cites this paper
• [Not Available].

  2014cites this paper
• Outcomes and management of viral hepatitis and human immunodeficiency virus co-infection in liver transplantation.

  2014cites this paper
• Triple antiviral therapy with telaprevir after liver transplantation: a case series

  2014cites this paper
• Evidence based management of hepatitis

  2014cites this paper
• Warfarin and boceprevir interaction causing subtherapeutic international normalized ratio: a case report

  2014cites this paper
• Investigating mechanisms of Hepatitis C virus endocytosis

  2014cites this paper
• Sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapy.

  2014cites this paper
• [Experience in the management of immunosuppressant treatment with hepatitis C virus protease inhibitors].

  2014cites this paper
• Interactions avec télaprévir ou bocéprévir chez des patients greffés hépatiques : à propos de 4 cas cliniques

  2014cites this paper
• Acute renal failure and liver toxicity in an HIV/hepatitis C coinfected patient receiving telaprevir and boosted atazanavir.

  2014cites this paper
• A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy.

  2014cites this paper
• Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential

  2014influential citation
• Drug interactions and protease inhibitors used in the treatment of hepatitis C: How to manage?

  2014cites this paper
• Clinical assessment of potential drug interactions of faldaprevir, a hepatitis C virus protease inhibitor, with darunavir/ritonavir, efavirenz, and tenofovir.

  2014cites this paper
• EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

  2014cites this paper
• Combination therapy with silibinin, pegylated interferon and ribavirin in a patient with hepatitis C virus genotype 3 reinfection after liver transplantation: a case report

  2014cites this paper
• Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin.

  2014cites this paper
• Management of acute and chronic HCV infection in persons with HIV coinfection.

  2014cites this paper
• [Drug-drug interaction with telaprevir or boceprevir in liver transplant patients: about four cases].

  2014cites this paper
• Renal impairment during the treatment of telaprevir with peginterferon and ribavirin in patients with chronic hepatitis C

  2014cites this paper
• Management of viral hepatitis in liver transplant recipients

  2014cites this paper
• Safety of direct-acting antivirals in the treatment of chronic hepatitis C

  2014influential citation
• Efficacy and safety of sofosbuvir-based therapy for the treatment of chronic hepatitis C in treatment-naïve and treatment-experienced patients.

  2014cites this paper
• The Role of Pharmacogenetics in the Treatment of Chronic Hepatitis C Infection

  2014cites this paper
• Hepatitis C and lipid metabolism, hepatic steatosis, and NAFLD: still important in the era of direct acting antiviral therapy?

  2014cites this paper
• New treatments for chronic hepatitis C: an overview for paediatricians.

  2014cites this paper
• Andrographolide exerts anti‐hepatitis C virus activity by up‐regulating haeme oxygenase‐1 via the p38 MAPK/Nrf2 pathway in human hepatoma cells

  2014cites this paper
• Validation of a sensitive LC/MS/MS method for the determination of telaprevir and its R-isomer in human plasma.

  2014cites this paper
• Comparison of first- and second-wave DAAs for HCV GT1: efficacy, safety, tolerability, and regimen complexity

  2014cites this paper
• Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting.

  2014influential citation
• Priapism induced by boceprevir-CYP3A4 inhibition and α-adrenergic blockade: case report.

  2014cites this paper
• Hepatitis C virus inhibitory hydrolysable tannins from the fruits of Terminalia chebula.

  2014cites this paper
• Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.

  2014cites this paper
• Targeting microRNA-122: walking on cutting edge of hepatitis C virus infection therapy.

  2014cites this paper
• Successful telaprevir treatment in combination of cyclosporine against recurrence of hepatitis C in the Japanese liver transplant patients.

  2014cites this paper
• Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations

  2014cites this paper
• Interactions Between Anti‐Infective Agents and Immunosuppressants in Solid Organ Transplantation

  2013influential citation
• In Vitro Assessment of Drug-Drug Interaction Potential of Boceprevir Associated with Drug Metabolizing Enzymes and Transporters

  2013influential citation
• Treatment of hepatitis C monoinfection in adults--Dutch national guidelines.

  2013cites this paper
• Polypharmacy and Comorbidity Are Associated with a Lower Early Virologic Response in Hepatitis C Patients Treated with First Generation Protease Inhibitor Triple Therapy: A Preliminary Analysis

  2013cites this paper
• Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.

  2013cites this paper
• CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core: Canadian guidelines for management and treatment of HIV/hepatitis C coinfection in adults.

  2013cites this paper
• HCV Enters the Twenty-First Century

  2013cites this paper
• Biochemical interaction of anti-HCV telaprevir with the ABC transporters P-glycoprotein and breast cancer resistance protein

  2013cites this paper
• Current and future therapies for hepatitis C virus infection.

  2013cites this paper
• Drug–Drug Interaction Studies: Regulatory Guidance and An Industry Perspective

  2013cites this paper
• A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail

  2013cites this paper